Edesa Biotech
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Spy Ct, Markham, Ontario, L3R 5H6, C...Phone Number
(289) 800-9600Website
www.edesabiotech.comRevenue
<$5 MillionStock Symbol
EDSAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Edesa Biotech
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a non-steroidal anti-inflammatory molecule for the treatment of chronic allergic contact dermatitis. Edesa Biotech is based in Markham, Canada, and was founded in 2007.Explore more
Edesa Biotech Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Edesa Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Edesa Biotech recently announced quarterly report
Click to see if Edesa Biotech had a recent Job posting/layoffs
Check if Edesa Biotech has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Edesa Biotech has new funding data
Product Launch: Get notified when Edesa Biotech launches new products
Check out if Edesa Biotech is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Edesa Biotech
Edesa Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Edesa Biotech as Masked Content
Find 3 more new buyers
Compare Similar Companies to Edesa Biotech
Compare insights from companies similar to Edesa Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Edesa Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Edesa Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Edesa Biotech.
Edesa Biotech financials insights
Gather financial insights about Edesa Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$7M
2026
Stock/Share Issuance
$3.5M
Edesa Biotech Tech Stack
A closer look at the technologies used by Edesa Biotech
Most Recent Scoops
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Edesa Biotech News & Media
Edesa Biotech Stock Sinks After Fresh Capital Raise
Edesa Biotech, Inc. (NASDAQ:EDSA) shares fell nearly 13% in Thursday premarket trading after the company priced a $25 million public stock offering. Edesa Biotech shares fell 18.27% to $4.70 in Wednesday’s after-market session, putting the stock on traders’ radars. The move followed the company’s Q3 earnings release, which came out four days earlier, according to Benzinga’s after-hours movers recap. What Is Edesa Biotech’s Financing Deal? Edesa is raising fresh capital via an equity offering ofEdesa Biotech Announces Pricing of $25.0 Million Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-fundedEdesa Biotech Announces Proposed Public Offering
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share warrants to purchase common shares. In addition, Edesa expects to grant the undeEdesa Biotech Reports Fiscal 3rd Quarter 2026 Results
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Edesa Biotech
Sign Up For FreeTo access detailed company insights
Edesa Biotech is a clinical-stage biopharmaceutical company focused on developing treatments that address significant unmet medical needs. Edesa's lead product candidate, EB01, is a non-steroidal anti-inflammatory molecule for the treatment of chronic allergic contact dermatitis. Edesa Biotech is based in Markham, Canada, and was founded in 2007.... Read More
